Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2349950 | 0.90 | KMT2A (0.40) | SMN1; SMN2MTNR1BELANEPTGDRPTGDR2 | |
| SCHEMBL2345719 | 0.90 | PTGDR (0.41) | SMN1; SMN2MTNR1BELANEPTGDRPTGDR2 | |
| SCHEMBL2351720 | 0.89 | HTR6 (0.42) | SMN1; SMN2MTNR1BELANEPTGDRPTGDR2 | |
| SCHEMBL2346554 | 0.86 | SMN1; SMN2 (0.44) | USP2SMN1; SMN2ELANEPTGDRPTGDR2 | |
| SCHEMBL2344548 | 0.86 | HTR6 (0.39) | SMN1; SMN2MTNR1BELANEPTGDRPTGDR2 | |
| SCHEMBL2345691 | 0.86 | HTR6 (0.39) | SMN1; SMN2ELANEPTGDRPTGDR2HTT | |
| SCHEMBL2350038 | 0.84 | ELANE (0.43) | SMN1; SMN2ELANEPTGDRPTGDR2 | |
| SCHEMBL2342085 | 0.84 | ELANE (0.40) | MTNR1BELANEPTGDRPTGDR2HTR6 | |
| Hydrochloric Acid SCHEMBL2349568 | 0.84 | ELANE (0.43) | SMN1; SMN2MTNR1BELANEPTGDRPTGDR2 | |
| SCHEMBL2351658 | 0.83 | ALDH1A1 (0.43) | SMN1; SMN2MTNR1BELANEPTGDRPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008295-B2 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-08-30 | — | — | US | disclosed |
| US-20100041652-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2010-02-18 | — | — | US | disclosed |
| US-20080008708-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2008-01-10 | — | — | US | disclosed |
| US-20060128783-A1 | Tyrosine kinase inhibitors | DINSMORE CHRISTOPHER J | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128783-A1 | Tyrosine kinase inhibitors | ABL1, ERBB2, JAK2 | USP2 2182/4885OPRK1 952/4885OPRM1 2271/4885 |
| US-20080008708-A1 | Tyrosine kinase inhibitors | ABL1, ERBB2, JAK2 | USP2 2182/4885OPRK1 952/4885OPRM1 2271/4885 |
| US-20100041652-A1 | TYROSINE KINASE INHIBITORS | ABL1, ERBB2, JAK2 | USP2 2182/4885OPRK1 952/4885OPRM1 2271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.